Insulet boosts sales force as pediatric pump sales grow; Derma Sciences reports positive preliminary Q4;

@FierceMedDev: Thermo nabs Chinese approval of $13.6B Life Tech merger. More | Follow @FierceMedDev

@MarkHFierce: Even N.Y. Sen. Chuck Schumer spilled the beans about Carlyle Group's bid for J&J's Ortho Clinical diagnostics arm. Story | Follow @MarkHFierce

@MichaelGFierce: Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Integra finalizes $235M deal for Covidien's surgical products line. News | Follow @EmilyWFierce

@GalenMoore: Bio-Path Holdings is raising $10M for its cancer drug delivery tech. Release | Follow @GalenMoore

> Insulet is expanding its sales force to accommodate growing pediatric insulin pump sales. Story

> California's Avantis Medical Systems raised nearly $1.8 million in new financing toward development of catheter-based endoscopic devices, initially for gastrointestinal tract cancers. Item

> Invision Heart in Nashville is building a smart, portable 12-lead EKG device that would upload patient data to the cloud so doctors can access it quickly. Story

> Derma Sciences ($DSCI), a major developer of medical devices and drugs focused on wound care, said it expects 2013 revenue to be up 7.7% compared to 2012. Item

> Castle Biosciences is promoting some encouraging early data for a predictive test it is developing for esophageal cancer. Item

Biotech News

@FierceBiotech: Merck clears an FDA panel with its clot-fighting vorapaxar. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Roche 's dealmakers at pRED will continue their global shopping spree in 2014. More | Follow @JohnCFierce

@DamianFierce: Sarepta still climbing on renewed hopes for eteplirsen. Article | Follow @DamianFierce

@EmilyMFierce: Per the FDA's new stance on antibacterials, here's a list of household products containing triclosan. | Follow @EmilyMFierce

> Amarin endures another FDA delay as Vascepa languishes. More

> J&J shipping out diagnostics biz for $4.2B. Report

> Gentium shareholders cry foul on $1B Jazz deal. News

Pharma News

@FiercePharma: FDA: The social media guidance puzzle will be complete by July. More | Follow @FiercePharma

@TracyStaton: Hungary joins the club of EU countries approving Novartis' generic version of GSK's blockbuster Advair. News | Follow @TracyStaton

@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Allergan rides high on patent backing for key drugs Lumigan and Restasis. Article | Follow @CarlyHFierce

> Actavis is pulling out of China; CEO says it's 'not worth the aggravation.' News

> FDA: The social media guidance puzzle will be complete by July. Story

> Impatient Bidvest prods Adcock for a deal as tussle with rival bidder escalates. Report

> J&J takes Carlyle's $4B offer for its Ortho Diagnostics unit. Item

Pharma Manufacturing News

> Merck recalls all lots of Liptruzet shipped since its May debut. Story

> Former Fresenius employee says he was fired for raising red flags. Article

> Premier supports new FDA compounder oversight plan. Report

> FDA assigns an agent to Europol in its fight against fakes. More

> Sources: Ranbaxy asks the FDA to let it make generic Diovan in U.S. News

> Actavis selling China assets as it exits that country. Item

Vaccines News

> CDC, FDA studies link Merck and GSK rotavirus vaccines to bowel blockages. Story

> BIO and Sanofi are pushing the FDA to tweak its drug shortage rule for vaccines. Story

> A Dendreon consultant has raised $8M for a cancer vaccine startup. Story

> Buzz: Merck and Novartis trying to iron out details of their business unit swap. Story

> AC Immune begins first trial of a tau-targeting Alzheimer's vaccine. Story

> Astellas and Takeda continue to advance vaccine strategies. Item

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.